Filing Summary
Moleculin Biotech, Inc. (NASDAQ: MBRX) furnished this Form 8-K on October 16, 2026, under Item 7.01, Regulation FD Disclosure. The filing announces that the company posted and is using an investor presentation dated October 16, 2026, identified as Exhibit 99.1. The presentation’s contents are not included in the supplied filing text.
Financial and Operating Information
The filing text does not provide revenue, profit, cash flow, margins, debt, liquidity, guidance, or other operating and financial metrics. It does not provide a clear basis for comparison with a prior period.
Disclosure and Investor Checks
- The information, including Exhibit 99.1, is furnished and is not deemed filed under the Exchange Act or incorporated by reference unless specifically identified in another filing.
- Review the full October 16, 2026 investor presentation to assess any business, clinical, financial, outlook, risk, or contingency claims; those details are not available in the supplied text.
- Verify any figures or forward-looking statements in the presentation against the company’s filed financial statements and other SEC disclosures.